NEW YORK, NY--(Marketwired - February 17, 2015) - Hansen Medical, Inc.'s (NASDAQ: HNSN) CEO Cary Vance discussed the company's robotic systems and catheters as well as their recent IVC filter retrieval breakthrough. Mr. Vance stated he believes Hansen's technology addresses many key trends and issues hospitals are facing today including revenue-generation and cost containment. He talked about some of the benefits the IVC filter provides patients such as much safer and more effective procedures. Mr. Vance outlined upcoming milestones, stating that Hansen expects to have a new 10 French Magellan Robotic Catheter to allow for new procedures in their vascular space. He also shared HNSN's global expansion strategy and goals for their electrophysiology business.


IsoRay, Inc. (NYSE: ISR) CEO Dwight Babcock talked about Cesium-131 and the recent positive results from a University of Pittsburg (UPMC) study. He explained the applications of ISR's technology, primarily in fighting against prostate cancer. Mr. Babcock also discussed the expansion of Cesium-131 in Russia and a case study in Peru, which used the company's proprietary technology to treat brain cancer in a patient who had tried and failed current standard of care methods. He provided examples of what makes Cesium-131 unique, and laid out how the company is going to expand their product. Finally, Mr. Babcock spoke about the significance of IsoRay being the fifth largest percentage gainer in the New York Stock Exchange Group for 2014.


Boston Therapeutics (OTCQB: BTHE) CEO Dr. David Platt provided an update on the company's recent developments since BTHE's previous interview with WSA, which included finalizing a phase II trial for type 2 diabetes. The company also began selling a food supplement, SUGARDOWN, which reduces the amount of sugar in the blood following a meal. Dr. Platt believes that Boston Therapeutics is setting itself apart from competitors by being the only company developing a non-systemic drug that blocks the intestinal enzyme that digests sugar. Adding to these statements, he provided a background of the company's management team and went over key goals for the next 12 months.

*Editor's Note: Since Boston Therapeutics' interview with WSA their Hong Kong Affiliate, Advance Pharmaceutical Company Ltd, has received a Department of Health Certificate to initiate their SUGARDOWN Clinical Trial.


About WSA:

The Wall Street Analyzer's aim is to provide investors with the tools they need to make informed decisions on holding stocks. Our staff includes a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand our financial experience gives us the ability to identify promising, off the grid companies before the rest of the market uncovers them, and on the other hand our media experience allows us to produce interviews, which appeal to a larger audience. We provide a format in which more individual investors can understand a featured companies' upside. Our philosophy is to turn stock tickers into stories, ideas into headlines, and technical and financial data into easier to understand data. Visit:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as SLWF or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, such statements in this release that describe the company's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, and risk inherent in the operations of a company. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events or other factors.

Contact Information:


Hansen Medical